ReviewJGH open : an open access journal of gastroenterology and hepatology2021
Gut microbiota dysbiosis in functional gastrointestinal disorders: Underpinning the symptoms and pathophysiology.
Review in JGH open : an open access journal of gastroenterology and hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 66 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Placebo-Controlled Clinical Trial To Evaluate The Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms
Effects of a Postbiotic Supplementation on Gastrointestinal and Core Symptoms in Autism Spectrum Disorder: A Multicenter Randomized Controlled Trial
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Bibliometric and visual analysis of gut microbiota research in functional bowel disorders from 2016 to 2025.Frontiers in medicine · 2026Pooled it
- European Consensus on Functional Bloating and Abdominal Distension-An ESNM/UEG Recommendations for Clinical Management.United European gastroenterology journal · 2025Guideline
- Microbiota in Autism Spectrum Disorder: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Trial
- Changes in Digestive Health, Satiety and Overall Well-Being after 14 Days of a Multi-Functional GI Primer Supplement.Nutrients · 2024Trial
- Efficacy of a Food Supplement ContainingNutrients · 2024Trial
- Trial
- Claudin-3 as a marker of intestinal permeability and its relation to inflammatory status in adolescents with functional gastrointestinal disorders.Pediatric research · 2026Article
- Immune dysregulation and gut microbiota: Connection to health and disease development.Neural regeneration research · 2026Article
- TMAO Correlates with Transcriptomic Signatures of Leukocyte Activation and Systemic Inflammation Following Burn Injury.Journal of burn care & research : official publication of the American Burn Association · 2026Article
- Solvent-Free Mechanochemical Synthesis, Antispasmodic Activity, and Integrated In Silico Mechanistic Analysis of a Dapsone-Derived Phenylaminojuglone.Biomolecules · 2026Article
- Beyond Medication: Integrative and Nutrition Therapies for Disorders of Gut-Brain Interaction.Gastroenterology & hepatology · 2026Article
- From Gut to Gain: The Microbiome's Contribution to Broiler Health and Productivity.Veterinary sciences · 2026Review
- A Cross-Sectional Dual-Site Analysis of the Gastric Antral and Duodenal Mucosa-Associated Microbiome Across Gastroesophageal Reflux Disease Phenotypes.Biomedicines · 2026Article
- Dietary index for gut microbiota (DI-GM) and irritable bowel syndrome: a case-control study.Scientific reports · 2026Article
- Clinical Evidence Linking the Gut Microbiome and Functional Dyspepsia: A Systematic Review and Meta-Analysis.Biomedicines · 2026Review
- What goes down may come up: regurgitative behaviors and their underlying gut-brain axes-insights from genetic models and related pathologies.Journal of comparative physiology. A, Neuroethology, sensory, neural, and behavioral physiology · 2026Review
- Microbiota-immune-enteric nervous system interactions in functional constipation: a narrative review and hypothesis-generating framework.Frontiers in immunology · 2026Review
- Pathophysiological Mechanisms and Nonpharmacological Interventions in Irritable Bowel Syndrome: Current Insights and Future Directions.Journal of nutrition and metabolism · 2026Review
- Correlation Between Dysbiosis and Atrial Fibrillation: What's New?International journal of molecular sciences · 2025Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional gastrointestinal disorders (FGIDs), currently known as disorders of gut-brain interaction, are emerging microbiota-gut-brain abnormalities that are prevalent worldwide. The pathogenesis of FGIDs is heterogeneous and is intertwined with gut microbiota and its derived molecule-modulated mechanisms, including gut dysmotility, visceral hypersensitivity, gut immune abnormalities, abnormal secretion, and impaired barrier function. There has been phenomenal progress in understanding the role of gut microbiota in FGIDs by underpinning the species alternations between healthy and pathological conditions such as FGIDs. However, the precise gut microbiota-directed cellular and molecular pathogeneses of FGIDs are yet enigmatic. Determining the mechanistic link between the gut microbiota and gastrointestinal (GI) diseases has been difficult due to (i) the lack of robust animal models imitating the various aspects of human FGID pathophysiology; (ii) the absence of longitudinal human and/or animal studies to unveil the interaction of the gut microbiota with FGID-relevant pathogenesis; (iii) uncertainty about connections between human and animal studies; and (iv) insufficient data supporting a holistic view of disease-specific pathophysiological changes in FGID patients. These unidentified gaps open possibilities to explore pathological mechanisms directed through gut microbiota dysbiosis in FGIDs. The current treatment options for dysbiotic gut microbiota are limited; dietary interventions, antibiotics, probiotics, and fecal microbiota transplantation are the front-line clinical options. Here, we review the contribution of gut microbiota and its derived molecules in gut homeostasis and explore the possible pathophysiological mechanisms involved in FGIDs leading to potential therapeutics options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.